Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells

Enavatuzumab is a humanized IgG1 anti-TWEAK receptor monoclonal antibody that was evaluated in a phase I clinical study for the treatment of solid malignancies. The current study was to determine whether and how myeloid effector cells were involved in postulated mechanisms for its potent antitumor a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Shiming, Fox, Melvin I., Belmar, Nicole A., Sho, Mien, Chao, Debra T., Choi, Donghee, Fang, Yuni, Zhao, Vivian, Keller, Stephen F., Starling, Gary C., Culp, Patricia A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623805/
https://www.ncbi.nlm.nih.gov/pubmed/29075649
http://dx.doi.org/10.1155/2017/5737159

Ejemplares similares

Ejemplares similares